PDCD1 and neoplasm: Tumor-associated LECs take on an immunosuppressive phenotype expressed by immune-inhibitory molecules, in which the programmed cell death 1 (PD-1) and its ligand PD-L1 are upregulated in tumor-associated lymphatic vessels [61,62].